Table 2

Cumulative Incidences at 2 Years of Cardiac Event Subgroups by Pre-Existing CHD Status

Event TypeTotal (N = 748)CHD Negative (n = 480)CHD Positive (n = 268)p Value
n (%)2-Year % (95% CI)n (%)2-Year % (95% CI)n (%)2-Year % (95% CI)
AHA/ACC MACE
 MACE, any77 (10.3)5.8 (4.3–7.7)27 (5.6)2.5 (1.4–4.2)50 (18.7)11.7 (8.2–15.9)<0.001
 CV death27 (3.6)1.6 (0.9–2.7)10 (2.1)0.6 (0.2–1.7)17 (6.3)3.4 (1.7–6.1)0.004
 CV death/nonfatal MI49 (6.6)3.3 (2.2–4.7)18 (3.8)1.7 (0.8–3.2)31 (11.6)6.0 (3.6–9.4)<0.001
Grade ≥3 CTCAE
 Any240 (32.1)23.3 (20.3–26.4)126 (26.3)19.0 (15.6–22.6)112 (42.5)31.0 (25.5–36.6)<0.001
 Arrhythmia128 (17.1)11.9 (9.7–14.4)64 (13.3)9.5 (7.1–12.3)64 (23.9)16.2 (12.1–20.9)0.001
 Coronary/cardiac arrest45 (6.0)2.3 (1.4–3.6)20 (4.2)0.8 (0.3–2.0)25 (9.3)4.9 (2.8–8.0)<0.001
 Heart failure/CM73 (9.8)5.5 (4.1–7.4)27 (5.6)2.7 (1.5–4.5)46 (17.2)10.5 (7.2–14.6)<0.001
 Pericardial, all types49 (6.6)4.6 (3.3–6.3)36 (7.5)6.1 (4.2–8.5)13 (4.9)1.9 (0.7–4.1)0.14
  Effusion, benign cyto.21 (2.8)1.8 (1.0–2.9)16 (3.3)2.8 (1.5–4.5)5 (1.9)0 (no events yet)0.24
 Valvulopathy16 (2.1)1.0 (0.4–1.9)8 (1.7)0.6 (0.2–1.8)8 (3.0)1.5 (0.5–3.6)0.24
 Cardiopulmonary/other56 (7.5)5.4 (3.9–7.2)33 (6.9)5.2 (3.5–7.5)23 (8.6)5.7 (3.3–8.9)0.42

ACC = American College of Cardiology; AHA = American Heart Association; CM = cardiomyopathy; CTCAE = common terminology criteria for adverse event; CV = cardiovascular; cyto. = cytology; MACE = major adverse cardiac event; other abbreviations as in Table 1.

  • Patients requiring pericardiocentesis with cytology showing no evidence of malignant cells. Estimates were compared using a 2-sided Gray’s p value.